Top Biotechnology companies in Denmark by Debt to Equity Ratio

This ranking features the top 11 Biotechnology companies in Denmark ranked by Debt to Equity Ratio, averaging a Debt to Equity Ratio of -0.59, for January 15, 2025.
#
Name
Debt to Equity Ratio
Reported Date
Stock Price
Change
Price (30 days) Country
1
0.55
Dec. 31, 2023 USD 54.16 -1.39%

Denmark

2
0.19
Dec. 31, 2023 USD 5.46 0.56%

Denmark

3
0.15
Dec. 31, 2023 USD 91.43 -1.85%

Denmark

4
0.12
Dec. 31, 2023 USD 0.20 -2.77%

Denmark

5
0.07
Dec. 31, 2023 USD 95.84 0.08%

Denmark

6
0.03
Dec. 31, 2023 USD 2.17 5.88%

Denmark

7
0.02
Dec. 31, 2023 USD 216.88 1.28%

Denmark

8
0.01
Dec. 31, 2023 USD 26.62 -0.36%

Denmark

9
0.01
June 30, 2024 USD 70.50 0.61%

Denmark

10
-3.25
Dec. 31, 2023 USD 0.57 1.47%

Denmark

11
-4.42
Dec. 31, 2023 USD 131.57 -1.84%

Denmark

Frequently Asked Questions
  • Which Biotechnology company in Denmark has the highest Debt to Equity Ratio ?

    The Biotechnology company in Denmark with the highest Debt to Equity Ratio is Novozymes A/S (Copenhagen Stock Exchange: NSIS-B.CO) at 0.55.

  • Which Biotechnology company in Denmark has the lowest Debt to Equity Ratio ?

    The Biotechnology company in Denmark with the lowest Debt to Equity Ratio is Ascendis Pharma A/S (NasdaqGS: ASND) at -4.42.